SCHEMBL4590047

SCHEMBL4590047

N=C(N)NCCCC(NC(=O)CN)C(=O)NC(Cc1ccccc1)C(=O)O.[Mn]

nearest known ligand 0.52

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
NPY4R P50391 13/20 0.52
NPY5R Q15761 8/20 0.52
NPY1R P25929 8/20 0.52
NPY2R P49146 5/20 0.52
QRFPR Q96P65 2/20 0.51
PTGER4 P35408 1/20 0.48
GNPAT O15228 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5598751 0.99 NPY4R (0.52) NPY4RNPY5RNPY1RNPY2RQRFPR
SCHEMBL5598748 0.99 NPY4R (0.52) NPY4RNPY5RNPY1RNPY2RQRFPR
SCHEMBL2249230 0.98 NPY4R (0.52) NPY4RNPY5RNPY1RNPY2RQRFPR
SCHEMBL30692729 0.95 GNPAT (0.54) NPY4RNPY5RNPY1RNPY2RQRFPR
SCHEMBL29447211 0.95 GNPAT (0.54) NPY4RNPY5RNPY1RNPY2RQRFPR
SCHEMBL30064048 0.93 NPY4R (0.59) NPY4RNPY5RNPY1RNPY2RQRFPR
SCHEMBL30264635 0.92 NPY4R (0.51) NPY4RNPY5RNPY1RNPY2RQRFPR
SCHEMBL31720889 0.92 NPY4R (0.54) NPY4RNPY5RNPY1RNPY2RQRFPR
SCHEMBL30782711 0.91 QRFPR (0.58) NPY4RNPY5RNPY1RNPY2RQRFPR
SCHEMBL31590213 0.91 NPY4R (0.62) NPY4RNPY5RNPY1RNPY2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255032-A1 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN PROCYTE CORPORATION (US) 2008-10-16 US disclosed
US-7384916-B2 Methods and compositions for preventing and treating aging or photodamaged skin PROCYTE CORPORATION (US) 2008-06-10 US disclosed
US-20060246029-A1 Methods and compositions for preventing and treating aging or photodamaged skin PROCYTE CORPORATION (US) 2006-11-02 US disclosed
US-20060018851-A1 Methods and compositions for preventing and treating hyperpigmentation of skin PROCYTE CORPORATION (US) 2006-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060246029-A1 Methods and compositions for preventing and treating aging or photodamaged skin RBP1, RBP4, SOD1 NPY4R 3564/4885NPY5R 2478/4885NPY1R 2475/4885
US-20060018851-A1 Methods and compositions for preventing and treating hyperpigmentation of skin RBP1, RBP4, MC1R NPY4R 3166/4885NPY5R 1383/4885NPY1R 1480/4885
US-20080255032-A1 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN RBP1, RBP4, SOD1 NPY4R 3564/4885NPY5R 2478/4885NPY1R 2475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.